{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:10:27Z","timestamp":1767802227520,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several maternal vaccines are in clinical development. Maternal respiratory syncytial virus (RSV) vaccine has been introduced in several high and upper middle-income countries. With the recent World Health Organization (WHO) RSV prevention recommendation and Gavi, the Vaccine Alliance\u2019s commitment to open a funding window for RSV maternal vaccine programs, the vaccine will soon be available for low- and middle-income markets. Understanding costs of implementing new maternal vaccines within existing health systems in low-and middle-income countries (LMICs) is critical to inform introduction decisions. This study projects the cost of maternal immunization (MI) introduction and delivery in Bangladesh and Nepal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using an activity based prospective costing approach, we project MI introduction and delivery costs for a five-year period in each country. In-country stakeholders informed the future MI delivery strategies used for costing. Interviews with immunization and maternal health program representatives informed activities and resource needs. Primary data from a sample of sub-national health administrative units including vaccine stores and health facilities also informed anticipated MI operational costs. Financial and economic costs to the health system are estimated and reported in 2023 US$ units.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Stakeholders confirmed utilizing existing maternal tetanus vaccine delivery systems as the most feasible strategy for future MI delivery in both countries. The non-vaccine cost of delivering one dose of maternal vaccine was estimated at $0.45 and $1.81 (financial) and $2.01 and $4.49 (economic) in Bangladesh and Nepal, respectively. Excluding commodity cost, health worker training and demand generation activities were among the largest cost drivers in both countries. Relatively lower unit costs in Bangladesh are partly due to larger target population size leading to some efficiency in introduction costs. The anticipated coverage and baseline health system capacity gaps also contribute to the variation in unit costs between countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MI delivery costs in LMICs are little known and this study contributes to filling this gap. These cost projections can equip countries to make informed introduction decisions as they evaluate the affordability and sustainability of MI programs in respective countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-25786-3","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T01:37:12Z","timestamp":1764725832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maternal vaccine delivery costs in South Asian settings: estimates from Bangladesh and Nepal"],"prefix":"10.1186","volume":"26","author":[{"given":"Ranju","family":"Baral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhiyan","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Monjurul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauri","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed M.","family":"Kashem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Mehedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iffat R.","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyabrata","family":"Routray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanto K.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Uranw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Pecenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"4","key":"25786_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/AOG.0000000000003161","volume":"133","author":"FM Munoz","year":"2019","unstructured":"Munoz FM, Jamieson DJ. Maternal immunization. Obstet Gynecol. 2019;133(4):739\u201353.","journal-title":"Obstet Gynecol"},{"key":"25786_CR2","unstructured":"Office of the Commissioner. FDA. FDA. 2024. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants."},{"key":"25786_CR3","unstructured":"Abrysvo | European Medicines Agency (EMA). 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo."},{"key":"25786_CR4","doi-asserted-by":"crossref","unstructured":"Pecenka C. RSV vaccination and immunoprophylaxis: realising the potential for protection of young children. Lancet. 2024. Forthcoming.","DOI":"10.1016\/S0140-6736(24)01699-4"},{"key":"25786_CR5","unstructured":"RSV vaccine and mAb snapshot. 2024. Available from: https:\/\/www.path.org\/our-impact\/resources\/rsv-vaccine-and-mab-snapshot\/."},{"key":"25786_CR6","unstructured":"Group B. Streptococcus (GBS). 2024. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/group-b-streptococcus-(gbs)."},{"key":"25786_CR7","unstructured":"Respiratory Syncytial Virus (RSV). Immunization Products. 2024. Available from: https:\/\/www.who.int\/groups\/strategic-advisory-group-of-experts-on-immunization\/working-groups\/respiratory-syncytial-virus-rsv-immunization-products."},{"key":"25786_CR8","unstructured":"Gavi welcomes first-ever prequalification of a maternal RSV vaccine. 2024. Available from: https:\/\/www.gavi.org\/news\/media-room\/gavi-welcomes-first-ever-prequalification-maternal-rsv-vaccine. Cited 12 Nov 2025."},{"key":"25786_CR9","unstructured":"Progress towards global MNT elimination. 2024. Available from: https:\/\/www.who.int\/initiatives\/maternal-and-neonatal-tetanus-elimination-(mnte)\/progress-towards-global-mnt-elimination."},{"key":"25786_CR10","unstructured":"GOV.UK. Introduction of new NHS vaccination programmes against respiratory syncytial virus (RSV). 2024. Available from: https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-rsv-vaccination-programmes-letter\/introduction-of-new-nhs-vaccination-programmes-against-respiratory-syncytial-virus-rsv."},{"issue":"12","key":"25786_CR11","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1080\/21645515.2020.1750248","volume":"16","author":"ML Giles","year":"2020","unstructured":"Giles ML, Mason EM, Lambach P, Mantel C. Maternal immunization country readiness: a checklist approach. Hum Vaccin Immunother. 2020;16(12):3177\u201383.","journal-title":"Hum Vaccin Immunother"},{"key":"25786_CR12","unstructured":"Maternal Immunization and Antenatal Care Situation analysis (MIACSA) project: results dissemination meeting report. Cape Town, South Africa: World Health Organization. 2024. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/330041\/WHO-MCA-19.06-eng.pdf?sequence=1."},{"key":"25786_CR13","unstructured":"Immunization Economics. Immunization Delivery Cost Catalogue. 2024. Available from: https:\/\/immunizationeconomics.org\/thinkwell-idcc\/."},{"issue":"40","key":"25786_CR14","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1016\/j.vaccine.2020.07.050","volume":"38","author":"SR Procter","year":"2020","unstructured":"Procter SR, Salman O, Pecenka C, Gon\u00e7alves BP, Paul P, Hutubessy R, et al. A review of the costs of delivering maternal immunisation during pregnancy. Vaccine. 2020;38(40):6199\u2013204.","journal-title":"Vaccine"},{"key":"25786_CR15","doi-asserted-by":"publisher","first-page":"126769","DOI":"10.1016\/j.vaccine.2025.126769","volume":"49","author":"R Baral","year":"2025","unstructured":"Baral R, Amponsa-Achiano K, Barros I, Cofie P, Fleming JA, Opoku Fofie C, et al. What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis. Vaccine. 2025;49:126769.","journal-title":"Vaccine"},{"issue":"11","key":"25786_CR16","doi-asserted-by":"publisher","first-page":"e084207","DOI":"10.1136\/bmjopen-2024-084207","volume":"14","author":"R Baral","year":"2024","unstructured":"Baral R, Otiang E, Odiyo J, Nyawanda BO, Nyiro JU, Munywaki PK, et al. Cost of delivering childhood RSV prevention interventions to the health system in kenya: a prospective analysis. BMJ Open. 2024;14(11):e084207.","journal-title":"BMJ Open"},{"key":"25786_CR17","doi-asserted-by":"publisher","first-page":"126654","DOI":"10.1016\/j.vaccine.2024.126654","volume":"45","author":"R Baral","year":"2025","unstructured":"Baral R, Barros I, Cofie P, Knudson S, Kumar S, Mehedi K, et al. What will it take? Perspectives from five low- and middle-income countries on opportunities and challenges of introducing new maternal vaccines. Vaccine. 2025;45:126654.","journal-title":"Vaccine"},{"key":"25786_CR18","unstructured":"WHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV). Vaccines. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-IVB-17.11. Cited 7 Aug 2024."},{"key":"25786_CR19","unstructured":"Brenzel L. Common approach for the costing and financing of routine immunization and new vaccines (EPIC). 2014."},{"key":"25786_CR20","unstructured":"World Health Organization. Guidelines for estimating costs of introducing new vaccines into the national immunization system. 2024. Available from: https:\/\/iris.who.int\/handle\/10665\/67342."},{"key":"25786_CR21","unstructured":"World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2024. Available from: https:\/\/iris.who.int\/handle\/10665\/329389."},{"key":"25786_CR22","first-page":"100069","volume":"5","author":"K Vaughan","year":"2020","unstructured":"Vaughan K, Ozaltin A, Moi F, Kou Griffiths U, Mallow M, Brenzel L. Reporting gaps in immunization costing studies: recommendations for improving the practice. Vaccine: X. 2020;5:100069.","journal-title":"Vaccine: X"},{"key":"25786_CR23","unstructured":"ABRYSVO\u00ae (Respiratory Syncytial Virus Vaccine.) Description | Pfizer Medical - US. Available from: https:\/\/www.pfizermedical.com\/abrysvo\/description. Cited 12 Nov 2025."},{"key":"25786_CR24","doi-asserted-by":"crossref","unstructured":"Hossain MT, Yesmin A, Islam MM, Moi F, Archer R, Boonstoppel L. Analysis of the Cost of COVID-19 Vaccine Delivery at Selected Sites in Bangladesh. Geneva: ThinkWell. 2024; Available from: https:\/\/thinkwell.global\/wp-content\/uploads\/2024\/03\/Study-report-Bangladesh-C19-vaccine-delivery-costing-study-vFinal-5-Feb-2024.pdf.","DOI":"10.1080\/21645515.2024.2411820"},{"issue":"9","key":"25786_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40273-020-00930-6","volume":"38","author":"A Portnoy","year":"2020","unstructured":"Portnoy A, Vaughan K, Clarke-Deelder E, Suharlim C, Resch SC, Brenzel L, et al. Producing standardized Country-level immunization delivery unit cost estimates. Pharmacoeconomics. 2020;38(9):995\u20131005.","journal-title":"Pharmacoeconomics"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-25786-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:42:49Z","timestamp":1767793369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-25786-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["25786"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-25786-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study activities adhered to the Declaration of Helsinki and was approved by the Bangladesh Medical Research Council (BMRC) ethics review committee in Bangladesh, and the Nepal Health Research Council (NHRC) and BP Koirala Institute of Health Sciences (BPKIHS) ethics review committees in Nepal. All study participants provided written informed consent to participate in the study prior to their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}